Table 2.
Univariate and multivariate analysis of survival in patients with colorectal cancer, treated with melphalan or mitomycin-C as a HIPEC agent.
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Characteristics | n | Median survival months (95%CI) | p-value | HR (95%CI) |
p-value |
| Agent | 0.54 | 0.24 | |||
| Melphalan | 18 | 36 (17-55) | 1.66 (0.7-3.95) | ||
| Mitomycin-C∗ | 27 | 28 (8-47) | |||
| Age | 0.42 | 0.24 | |||
| ≤53∗ | 31 | 37 (23-51) | |||
| >53 | 14 | 30 (11-49) | 1.62 (0.72-3.64) | ||
| CC score | 0.026 | 0.69 | |||
| CC-0∗ | 37 | 36 (24-49) | |||
| CC-1 | 8 | 24 (3-47) | 1.25 (0.43-3.64) | ||
| PCI | <0.001 | <0.001 | |||
| ≤20∗ | 24 | 46 (29-64) | |||
| >20 | 20 | 18 (12-24) | 7.5 (2.76-20.4) | ||
| LN status | 0.49 | 1 | |||
| no LN metastases∗ | 22 | 37 (35-39) | |||
| LN metastases | 19 | 27 (18-35) | 1 (0.44-2.27) | ||
HR: hazard ratio; CI: confidence interval; PCI: peritoneal carcinomatosis index; LN: lymph nodes; ∗used as reference; patients with >1 CRS/HIPEC were excluded from the analysis.